von Hippel-Lindau (VHL) is a critical tumor suppres- sor in clear cell renal cell carcinomas (ccRCCs). It is important to identify additional therapeutic targets in ccRCC downstream of VHL loss beside
β-catenin tends to regulate its target genes, and the dysregulation of Wnt/b-catenin signaling facilitated hallmarks of colorectal cancer (CRC). Identification of β-catenin targets and their potential